CR20120115A - Terapia de combinacion con composiciones de nanoparticulas de taxano e inhibidores de hedgehog - Google Patents

Terapia de combinacion con composiciones de nanoparticulas de taxano e inhibidores de hedgehog

Info

Publication number
CR20120115A
CR20120115A CR20120115A CR20120115A CR20120115A CR 20120115 A CR20120115 A CR 20120115A CR 20120115 A CR20120115 A CR 20120115A CR 20120115 A CR20120115 A CR 20120115A CR 20120115 A CR20120115 A CR 20120115A
Authority
CR
Costa Rica
Prior art keywords
hedgehog
combination therapy
nanoparticules
taxan
inhibitors
Prior art date
Application number
CR20120115A
Other languages
English (en)
Inventor
Chunlin Tao
Neil P Desai
Patrick Soon-Shiong
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of CR20120115A publication Critical patent/CR20120115A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos de terapia de combinación para tratar una enfermedad proliferativa (tal como cáncer) que comprende administrar a un individuo una cantidad efectiva de un taxano en una composición de nanopartículas y un inhibidor de hedgehog que inhibe una ruta de señalización de hedgehog.
CR20120115A 2009-08-25 2012-03-12 Terapia de combinacion con composiciones de nanoparticulas de taxano e inhibidores de hedgehog CR20120115A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23681309P 2009-08-25 2009-08-25

Publications (1)

Publication Number Publication Date
CR20120115A true CR20120115A (es) 2012-09-04

Family

ID=43628371

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120115A CR20120115A (es) 2009-08-25 2012-03-12 Terapia de combinacion con composiciones de nanoparticulas de taxano e inhibidores de hedgehog

Country Status (26)

Country Link
US (2) US20130045240A1 (es)
EP (2) EP3103452A1 (es)
JP (1) JP2013503174A (es)
KR (1) KR20120053052A (es)
CN (1) CN102573832B (es)
AU (1) AU2010286670B2 (es)
BR (1) BR112012004149A2 (es)
CA (1) CA2772301A1 (es)
CR (1) CR20120115A (es)
DK (1) DK2470173T3 (es)
ES (1) ES2577024T3 (es)
HR (1) HRP20160551T8 (es)
HU (1) HUE029094T2 (es)
IL (1) IL218316A (es)
IN (1) IN2012DN02018A (es)
MX (1) MX340670B (es)
MY (1) MY162514A (es)
NI (1) NI201200030A (es)
NZ (1) NZ598588A (es)
PL (1) PL2470173T3 (es)
PT (1) PT2470173E (es)
RU (1) RU2561055C2 (es)
SG (2) SG178873A1 (es)
UA (1) UA110196C2 (es)
WO (1) WO2011025838A1 (es)
ZA (1) ZA201201531B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
LT3311805T (lt) * 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
EP2131821B1 (en) * 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
JP5579057B2 (ja) * 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
US8748623B2 (en) 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
US20130109672A1 (en) * 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
CA2801314A1 (en) * 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
JP6031437B2 (ja) * 2010-06-07 2016-11-24 アブラクシス バイオサイエンス， エルエルシー 増殖性疾患を処置するための組み合わせ療法
EP2608672B1 (en) * 2010-08-23 2020-12-16 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
KR101970342B1 (ko) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
EP2806948B1 (en) 2012-01-27 2020-01-15 New York University Method for enhancing remyelination using gli1 inhibitors
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
EP2906212A4 (en) * 2012-10-15 2016-06-08 Agios Pharmaceuticals Inc THERAPEUTIC COMPOUNDS AND COMPOSITIONS
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
WO2014087413A1 (en) * 2012-12-03 2014-06-12 Vishwa Vidya Peetham University Amrita Nanoparticles comprising sorafenib
US20140186447A1 (en) * 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9776996B2 (en) * 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014179678A1 (en) * 2013-05-03 2014-11-06 Angiostrass Llc Methods of treating cancer and angioproliferative disorders
WO2014196793A1 (en) * 2013-06-05 2014-12-11 C&C Research Laboratories Heterocyclic derivatives and use thereof
AR096788A1 (es) 2013-07-02 2016-02-03 Bristol Myers Squibb Co Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
WO2015002926A1 (en) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
JP2016537399A (ja) 2013-09-17 2016-12-01 ジェネンテック， インコーポレイテッド 抗ｌｇｒ５抗体を使用する方法
GB201416513D0 (en) * 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
MX394452B (es) 2015-02-27 2025-03-21 Curtana Pharmaceuticals Inc Inhibicion de la actividad de olig2.
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CN107709314A (zh) 2015-06-11 2018-02-16 巴斯利尔药物国际股份公司 外排泵抑制剂及其治疗性用途
ES3009356T3 (en) 2015-06-29 2025-03-26 Abraxis Bioscience Llc Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
CN106421786A (zh) * 2015-08-06 2017-02-22 复旦大学 Hedgehog通路抑制剂和纳米药物递送系统的药物组合物及其用途
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
MX2021014686A (es) * 2019-05-29 2022-04-06 Nelum Corp Métodos y usos para tratar el cáncer.
BR112022007710A2 (pt) 2019-10-28 2022-07-12 Abraxis Bioscience Llc Composições farmacêuticas de albumina e rapamicina
CN112755042A (zh) * 2019-11-06 2021-05-07 绍兴维帆生物技术有限公司 一种抗肿瘤药物的联合使用治疗白血病的方法
KR102526793B1 (ko) * 2021-11-03 2023-04-28 주식회사 에스엔바이오사이언스 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법
WO2025120551A1 (ko) * 2023-12-08 2025-06-12 제이더블유중외제약 주식회사 헤테로사이클 유도체 제조에 사용되는 중간체 화합물, 이의 제조 방법 및 이를 이용한 헤테로사이클 유도체의 제조 방법
WO2025120550A1 (ko) * 2023-12-08 2025-06-12 제이더블유중외제약 주식회사 헤테로사이클 유도체 제조에 사용되는 중간체 화합물, 이의 제조 방법 및 이를 이용한 헤테로사이클 유도체의 제조 방법
CN120177781B (zh) * 2025-05-22 2025-08-12 南京师范大学 生物传感器及其应用和高通量筛选花姜酮生产菌的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
PT1023050E (pt) * 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
WO2000025725A2 (en) 1998-11-02 2000-05-11 Biogen, Inc. Functional antagonists of hedgehog activity
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
EP1119368A2 (en) 1999-03-03 2001-08-01 Biogen, Inc. Methods of modulating lipid metabolism and storage
AU782493B2 (en) 1999-06-01 2005-08-04 Curis, Inc. Polymer conjugates of hedgehog proteins and uses
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
US20050192262A1 (en) * 2001-03-13 2005-09-01 Tomas Hagstrom Treatment of tumours
BR0211513A (pt) 2001-07-27 2005-08-30 Curis Inc Mediadores de caminhos sinalizantes de hedgehog, composições e usos relacionados ao mesmo
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
EP1496905B1 (en) 2002-04-22 2008-08-13 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
FR2850022B1 (fr) * 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
JP2008514726A (ja) * 2004-09-30 2008-05-08 ザ ユニヴァーシティー オヴ シカゴ ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
EP1807074B1 (en) * 2004-11-03 2013-10-23 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
EP3527202A1 (en) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
US20080019961A1 (en) 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
DE102006038747A1 (de) 2006-08-17 2008-03-20 Khs Ag Dichtanordnung für eine Drehlagervorrichtung
JP4897518B2 (ja) 2007-03-02 2012-03-14 株式会社ニチベイ ブラインドの操作装置
SG179418A1 (en) * 2007-03-14 2012-04-27 Exelixis Patent Co Llc Inhibitors of the hedgehog pathway
CA2681162C (en) * 2007-03-15 2015-11-24 Novartis Ag Benzyl and pyridine derivatives as modulators of hedgehog pathway
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
BR122021010386B1 (pt) * 2007-06-07 2021-08-03 Sun Pharma Global Fze Uso de n-(6-((2r,6s)-2,6-dimetilmorfolino)piridin-3-il)-2-metil-4'-(trifluorometoxi) bifenil-3- carboxamida como moduladores da rota de hedgehog
US20090123932A1 (en) * 2007-11-09 2009-05-14 Anne-Marie Mes-Masson Quantitative test to detect disease progression markers of epithelial ovarian cancer patients
PE20091180A1 (es) 2007-12-27 2009-08-26 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer
US8030454B2 (en) * 2007-12-28 2011-10-04 Genentech, Inc. Anti-hedgehog antibodies

Also Published As

Publication number Publication date
US20130045240A1 (en) 2013-02-21
HRP20160551T1 (hr) 2016-09-23
NI201200030A (es) 2012-12-06
RU2561055C2 (ru) 2015-08-20
RU2012111235A (ru) 2013-10-10
ZA201201531B (en) 2013-05-29
HRP20160551T8 (hr) 2016-11-18
MY162514A (en) 2017-06-15
EP3103452A1 (en) 2016-12-14
NZ598588A (en) 2014-05-30
CN102573832B (zh) 2015-07-22
AU2010286670B2 (en) 2016-04-21
UA110196C2 (uk) 2015-12-10
EP2470173A1 (en) 2012-07-04
IL218316A0 (en) 2012-04-30
EP2470173B1 (en) 2016-04-27
MX2012002460A (es) 2012-05-08
CN102573832A (zh) 2012-07-11
AU2010286670A1 (en) 2012-03-29
SG178873A1 (en) 2012-04-27
MX340670B (es) 2016-07-20
ES2577024T3 (es) 2016-07-12
US20140072630A1 (en) 2014-03-13
CA2772301A1 (en) 2011-03-03
IN2012DN02018A (es) 2015-07-31
PL2470173T3 (pl) 2016-11-30
IL218316A (en) 2016-04-21
KR20120053052A (ko) 2012-05-24
BR112012004149A2 (pt) 2016-03-22
WO2011025838A1 (en) 2011-03-03
JP2013503174A (ja) 2013-01-31
DK2470173T3 (en) 2016-06-06
HK1172550A1 (zh) 2013-04-26
SG10201609290PA (en) 2016-12-29
HUE029094T2 (hu) 2017-02-28
PT2470173E (pt) 2016-06-15
EP2470173A4 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
CR20120115A (es) Terapia de combinacion con composiciones de nanoparticulas de taxano e inhibidores de hedgehog
CO6321188A2 (es) Tratamiento de cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de parp
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
MY162903A (en) Methods of treatment of pancreatic cancer
MY166014A (en) Combination therapy methods for treating proliferative diseases
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
BR112012024349A2 (pt) métodos de tratamento de carcinoma hepatocelular
CR20120528A (es) Métodos para tratar el cáncer
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
CR20120202A (es) Métodos y composiciones para tratar cáncer
ECSP099376A (es) Inhibidores de la actividad de la akt
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2013003076A (es) Terapeuticos contra cancer de mama.
MX359227B (es) Tratamiento de cáncer con inhibidores de tor cinasa.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
BR112012011823A2 (pt) métodos e composições para tratar tumores sólidos e outras malignidades
GT201200279A (es) Combinaciones de principios activos
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
CR20140211A (es) Terapia de combinación para cáncer de ovario
DOP2014000221A (es) Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek
BR112015025101A2 (pt) composição antitumoral que compreende um inibidor pi3kbeta-seletivo e um inibidor pi3kalfa-seletivo
NI201300052A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
GT201300148A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de p13k y un inhibidor de mek